OMAHA, Neb.--(BUSINESS WIRE)--
Transgenomic, Inc. (TBIO) (NASDAQ: TBIO), today announced that it has signed agreements with two additional distributors in China and India for its ICEme™ Mutation Enrichment Kits for cancer genomic testing. The kits incorporate Transgenomic’s Multiplexed ICE COLD-PCR (MX-ICP) technology and are designed to enable virtually any laboratory to conduct high quality DNA mutation detection in cancer patients using plasma, blood or tissue samples and existing sequencing platforms. The new distributors, JoyingBio in China and Biotron Healthcare in India, are important suppliers of advanced life science products in their respective markets.
“Asia represents large and growing healthcare sectors, and our ICEme Kits will allow researchers and clinicians in the rapidly expanding markets of China and India to use the sequencing platforms already in their labs to conduct sophisticated genetic analyses to accelerate cancer research and advance patient care,” commented Paul Kinnon, President and Chief Executive Officer of Transgenomic. “We decided to work with these new distributors in response to the increasingly robust demand we are seeing in Asia for our ICEme Kits, which we believe reflects the exceptional accuracy, versatility and ease of use of our unique ICP technology.”
ICEme technology delivers up to a 500-fold increase in mutation detection compared to most current methods, with levels of detection routinely achievable down to 0.01%. This ultra-high sensitivity enables detection of low level mutations that allow accurate patient monitoring as well as stratification of cancer sub-populations. ICEme Kits work well with most patient samples, including tissue, blood, plasma, urine and other biofluids. The kits are simple to use and work with most of the downstream genomic analytic platforms commonly available in laboratories today. They are easily customizable for use with single mutations or in combination. The current menu includes approximate 20 clinically relevant, actionable mutations that are associated with important cancers such as colorectal, lung, breast and melanoma. Additional mutations are being added on an ongoing basis.
Additional information on the ICEme kits is available at www.transgenomic.com/products/iceme-kits-overview/.
Multiplexed ICE COLD-PCR was originally developed by the laboratory of Dr. Mike Makrigiorgos at the Dana-Farber Cancer Institute, which has exclusively licensed rights to the technology to Transgenomic.
About Transgenomic
Transgenomic,
Inc. is a global biotechnology company advancing personalized
medicine in oncology and inherited diseases through advanced diagnostic
technologies, such as its revolutionary ICE COLD-PCR, which enables use
of liquid biopsies for mutation detection. The company also provides
specialized clinical and research services to biopharmaceutical
companies developing targeted therapies. Transgenomic’s diagnostic
technologies are designed to improve medical diagnoses and patient
outcomes.
Forward-Looking Statements
Certain statements in this
press release constitute “forward-looking statements” of Transgenomic
within the meaning of the Private Securities Litigation Reform Act of
1995, which involve known and unknown risks, uncertainties and other
factors that may cause actual results to be materially different from
any future results, performance or achievements expressed or implied by
such statements. Forward-looking statements include, but are not limited
to, those with respect to management's current views and estimates of
future economic circumstances, industry conditions, company performance
and financial results, including the ability of the Company to grow its
involvement in the diagnostic products and services markets,
expectations regarding new clients, projects and prospects, and MX-ICP’s
ability to accelerate the Company’s growth and generate revenue. The
known risks, uncertainties and other factors affecting these
forward-looking statements are described from time to time in
Transgenomic's filings with the Securities and Exchange Commission. Any
change in such factors, risks and uncertainties may cause the actual
results, events and performance to differ materially from those referred
to in such statements. Accordingly, the Company claims the protection of
the safe harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995 with respect to all statements
contained in this press release. All information in this press release
is as of the date of the release and Transgenomic does not undertake any
duty to update this information, including any forward-looking
statements, unless required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160929005146/en/
